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Suboptimal (ie, <100%) antiretroviral therapy (ART) adher-
ence has been associated with heightened inflammation in 
cohort studies, even among people with virologic suppression. 
We aimed to evaluate this association among participants in the 
Strategies for Management of Antiretroviral Therapy (SMART) 
study who had virologic suppression (HIV-1 VL < 200 copies/
mL) at enrollment. Based on self-reported adherence (7-day 
recall), plasma concentrations of interleukin 6 and D-dimer 
were 9% (95% confidence interval [CI], 1%–18%; P = .02) and 
11% (95% CI, 1%–22%; P  =  .03) higher in participants who 
reported suboptimal vs 100% adherence, respectively. These 
findings confirm previous observations and support the hypoth-
esis that suboptimal ART adherence, even in the context of viro-
logic suppression, may have significant biological consequences.
ClinicalTrials.gov number NCT00027352
Keywords. adherence; antiretroviral therapy; inflamma-
tion; SMART study. 
While suppressive antiretroviral therapy (ART) has allowed for 
improved survival in people living with HIV (PLWH), these 
individuals exhibit a state of chronic residual inflammation, 
immune activation, and coagulopathy that, on average, does not 
revert to the levels observed in their HIV-negative counterparts 
[1]. This residual inflammation has been associated with the 
development of serious non-AIDS adverse events (SNAEs) such 
as cardiovascular disease, cancer, and death [2, 3]. To date, the 
mechanisms behind this immune dysregulation remain poorly 
understood, which has limited the efforts to identify interven-
tions that can successfully reverse it. Thus, it remains imperative 
to identify new and effective strategies to achieve this goal.
Recently, suboptimal ART adherence has emerged as a poten-
tial contributor to residual inflammation in PLWH, even if it is 
sufficient to achieve and sustain plasma viral suppression through 
conventional assays [4, 5]. Cohort-derived data suggest that sub-
optimal (ie, less than 100%) adherence is associated with higher 
levels of residual inflammation, immune activation, and activation 
of coagulation in PLWH who have virologic suppression while on 
ART [4, 5]. These observations have emphasized the potential bio-
logical differences that could exist between complete and subopti-
mal ART adherence in order to maximize the therapeutic benefit 
of ART. Whether these associations can also be identified in a large, 
multinational diverse population remains unknown. To evaluate 
this, we aimed to study the association of ART adherence with 
inflammation and activation of coagulation in virologically sup-
pressed PLWH on chronic ART who were enrolled in the Strategies 
for Management of Antiretroviral Therapy (SMART) study.
METHODS
Participants
The SMART study (NCT00027352) was a multinational, ran-
domized clinical trial performed in 5472 PLWH (women and 
men older than 13 years) between 2002 and 2006; SMART study 
details and main results were previously published [6]. The trial 
included PLWH who were or were not on ART upon enrollment 
without restriction according to viral load (VL) [6]. In this ret-
rospective analysis, we evaluated participants who at enrollment: 
(1) were on ART, (2) had completed an adherence questionnaire, 
and (3) had an HIV-1 VL measurement available. Given our 
goal of evaluating the association between adherence and resid-
ual inflammation and coagulopathy beyond virologic suppres-
sion, we focused our study population to individuals who were 
virologically suppressed to at least <200 copies/mL (and to <50 
copies/mL if this lower threshold was available) and limited our 
analysis to the enrollment visit only. All study procedures were 
reviewed and approved by the local institutional review boards, 
and all participants provided written informed consent.
Adherence Assessment
Adherence was measured (within 45 days of randomization) 
by participant self-report using the Terry Beirn Community 
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Programs for Clinical Research on AIDS (CPCRA) 
Antiretroviral Medication Self-Report Form 065-BAS-2, 
which uses a 7-day global recall in which participants can 
respond whether they took “all,” “most,” “about one-half,” 
“very few,” or “none” of their pills for each specific pill in 
their ART regimen. This is a validated adherence measure 
that predicted the development of viral rebound in people 
with viral suppression in the SMART study [7, 8]. Adherence 
was labeled “suboptimal” if a participant reported any option 
other than taking “all of my pills” for at least 1 antiretroviral 
medication (calculated adherence < 100%), and “100%” if a 
participant reported taking “all of my pills” for all ART med-
ications [8].
Biomarkers of Inflammation and Activation of Coagulation
Plasma levels of interleukin 6 (IL-6), high-sensitivity C-reactive 
protein (hsCRP), and D-dimer were measured in plasma sam-
ples collected at enrollment using EDTA tubes (and stored/
shipped frozen) in a subset of the enrolled and randomized 
participants, as previously reported [3]. These biomarkers were 
measured by the Laboratory for Clinical Biochemistry Research 
at the University of Vermont. IL-6 was measured by ultrasensi-
tive enzyme-linked immunosorbent assay (ELISA; Quantikine 
HS Human IL-6 Immunoassay; R&D Systems), with a lower 
limit of detection (LLOD) of 0.16 pg/mL. hsCRP was measured 
using the BNII nephelometer (N High Sensitivity CRP; Siemens 
Healthcare Diagnostics), with an LLOD of 0.16 µg/mL. D-dimer 
was measured using immunoturbidimetric assay (Liatest D-DI; 
Diagnostica Stago), with an LLOD of 0.01 µg/mL, as previously 
described [3].
Statistical Analysis
Participant demographic and baseline cohort characteristics 
were summarized using the appropriate statistical measures. 
Adherence was dichotomized as 100% and suboptimal (<100%). 
Biomarker plasma concentrations were log-transformed before 
analysis to address skewing of data. Initially, the relationship 
between ART adherence and the baseline concentrations of 
the biomarkers was graphically analyzed using scatterplots. 
We then utilized univariate and multivariable linear regression 
analysis to evaluate the association between adherence and 
the log-transformed concentrations of biomarkers at baseline, 
adjusting for covariates that have previously been associated 
with biomarkers of inflammation and coagulopathy in SMART 
and other cohorts [9–13], including age, race, gender, body 
mass index, time since start of ART, HIV exposure group, base-
line viral load, baseline and nadir CD4+ T-cells, co-infection 
with hepatitis B or C, smoking, and ART regimen type based 
on anchor drug. Data are presented as fold differences (95% CI) 
in biomarker concentrations in participants who were subopti-
mally vs 100% adherent. All statistical analyses were performed 
using SAS version 9.4. A P value <.05 was considered statisti-
cally significant.
RESULTS
Study Participants
At the baseline visit, a total of 3963 participants were tak-
ing ART and had both a completed adherence questionnaire 
and an HIV-1 RNA VL measurement. Of these, 3056 partici-
pants (77%) were virologically suppressed to <200 copies/mL 
and were included in the analysis (Supplementary Figure). 
Additional demographic and baseline characteristics of the 
study participants are shown in Table 1.
ART Adherence and Biomarkers of Inflammation and Activation of 
Coagulation
Of the 3056 virologically suppressed participants analyzed, 
404 (13%) reported suboptimal adherence at the baseline 
visit (Table  1). The distribution of time between HIV VL 
Table 1. Demographic Characteristics of Study Participants
Characteristic (n = 3056) No. (%) or Median (IQR)
Demographics
 Age, median (IQR), y 44 (38–51) 
 Women 827 (27%)
Race
 White 1519 (50%)
 Black 696 (23%)
 Hispanic 570 (19%)
 Asian 200 (7%)
 Other 71 (2%)
Country of origin
 Non-US 1859 (61%)
 US 1197 (39%)
HIV exposure group
 MSM 1498 (49%)
 Heterosexual 1156 (38%)
 IDU 239 (8%)
 Other 163 (5%)
BMI, median (IQR), kg/m2 24.5 (22.1–27.4) 
Smoking (current) 1138 (37%)
HBV infection 69 (2%)
HCV infection 130 (4%)
Time since start of ART, y
 <1 72 (2%)
 1–5 1082 (35%)
 >5 1895 (62%)
Antiretroviral regimen
 NNRTI-based 1388 (45%)
 PI-based 1164 (38%)
 Other 504 (16%)
Baseline CD4+ T-cells, median (IQR), cells/mm3 649 (496–842) 
Nadir CD4+ T-cells, median (IQR), cells/mm3  230 (136–329) 
HIV VL <50 copies/mL 2371 (78%)
Adherence (7-d)
 100% adherence 2652 (87%)
 Suboptimal adherence 404 (13%)
Abbreviations: ART, antiretroviral therapy; BMI, body mass index; HBV, hepatitis B virus; 
HCV, hepatitis C virus; IDU, injection drug users; IQR, interquartile range; MSM, men who 
have sex with men; NNRTI, non-nucleoside reverse transcriptase inhibitor; PI, protease 
inhibitor.
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measurement and biomarker measurement was (min, percen-
tiles, and max): min –69 days, 1st –43 days, 5th –36 days, 10th 
–30 days, 25th –16 days, 50th 0 days, 75th 0 days, 90th 0 days, 
95th 0 days, and 99th 14 days, max 40 days. IL-6, D-dimer, and 
hsCRP baseline biomarker data were available in 2763, 2776, and 
2793 participants who fulfilled the other criteria, respectively. 
The distribution of biomarker concentrations in suboptimally 
vs 100% adherent participants who had available biomarker 
data at the baseline visit is shown in Table  2. In a univariate 
model, baseline IL-6, D-dimer, and hsCRP were 16% (95% CI, 
1.06–1.26; P =  .0005), 17% (95% CI, 1.05–1.29; P =  .002), and 
7% (95% CI, 0.94–1.23; P = .31) fold higher in participants who 
reported suboptimal adherence in comparison with those with 
who reported 100% adherence, respectively (Table 2). This asso-
ciation remained significant for both IL-6 and D-dimer in an 
adjusted model, where IL-6 was 9% (95% CI, 1.01–1.18; P = .02) 
and D-dimer was 11% (95% CI, 1.01–1.22; P = .03) higher in sub-
optimally adherent participants (Table  2). Similar results were 
observed in a sensitivity analysis restricted to participants with 
HIV-1 VL <50 copies/mL (n = 2371) (Supplementary Table).
DISCUSSION
In this analysis, we identified a significant inverse association 
between ART adherence and systemic inflammation and activa-
tion of coagulation in virologically suppressed (<200 copies/mL) 
PLWH at the time of their enrollment in SMART. The magnitude 
of this association ranged between 9% and 11% higher for levels 
of IL-6 and D-dimer, respectively, in participants reporting sub-
optimal vs 100% adherence after adjusting for multiple potential 
confounders such as smoking, body mass index, baseline and 
nadir CD4+ T-cell count, time since start of ART, and drug reg-
imen. In addition, these findings also remained significant after 
restricting our analysis to participants who were suppressed 
to <50 copies/mL. To our knowledge, this is the first study to 
demonstrate an association between adherence to ART and bio-
markers of inflammation and coagulopathy in a virologically 
suppressed diverse international population on chronic ART.
Our study reaffirms previous cohort findings in which sub-
optimal adherence, measured by self-report [4] and Medication 
Event Monitoring System [5], was associated with a similar 
degree of increased residual inflammation and coagulopathy, 
supporting the hypothesis that ART adherence has signifi-
cant repercussions that extend beyond virologic suppression. 
However, our findings are contrary to recent studies in which 
short cycle ART interruptions (4 or 5 days on, 3 or 2 days off) 
maintained viral suppression in PLWH, and where no differ-
ences in inflammatory biomarkers were identified [14, 15]. 
These discrepancies could be due to differences in study pop-
ulations (ie, short cycle studies generally recruited preselected 
participants with long-standing suppression), the small sample 
size, and the nonrandomized nature of most of these studies. 
While this therapeutic forgiveness of modern ART has usu-
ally been regarded as advantageous in clinical practice, it has 
 de-emphasized the focus on achieving optimal adherence. It has 
also allowed permissiveness to missed doses, as long as virologic 
suppression is maintained. Further studies to better understand 
the role of this “suppressive adherence gap” on the pathogen-
esis of chronic residual inflammation in treated HIV disease 
are required, including additional studies evaluating treatment 
interruptions and studies focused on long-acting ART.
In regards to potential explanatory mechanisms behind 
our findings, suboptimal ART adherence could contribute to 
residual inflammation and coagulopathy in a variety of possi-
ble ways, which include (1) residual viral replication below the 
limit of detection of clinically available assays (which may lead 
to persistently enhanced inflammation and immune activa-
tion) [16, 17], (2) ongoing viral replication at sanctuary sites (ie, 
lymph node), where antiretroviral drug concentrations are low 
as a result of limited tissue penetration and/or low adherence 
(leading to viral escape and subsequent inflammation) [18], or 
(3) intermittent episodes of viremia that are not captured at the 
time of viral load assessment in a clinical or research setting 
(ie, missed viremia resulting in intermittent bursts of inflam-
mation and immune activation). Given the limited impact that 
Table 2. Distribution of Biomarker Concentrations in Participants With Available Baseline Data According to Adherence Category and Fold Difference in 
Available Baseline Inflammatory and Coagulopathy Biomarker Plasma Concentrations in Suboptimally Adherent, Virologically Suppressed PLWH on ART 
Enrolled in SMART
Biomarker
Unadjusted Analysis Adjusted Analysisa
100% Adherence
Suboptimal 
Adherence Fold Higher Level 
Compared With 
100% Adherenceb 95% CI P Value
Fold Higher Level 
Compared With 100% 
Adherenceb 95% CI P ValueNo. Mean (SD) No. Mean (SD)
IL-6, pg/mL 2372 2.60 (6.93) 391 2.93 (4.53) 1.16 1.06–1.26 .0005 1.09 1.01–1.18 .02
D-dimer, μg/mL 2382 0.30 (0.59) 394 0.38 (1.06) 1.17 1.05–1.29 .002 1.11 1.01–1.22 .03
hsCRP, μg/mL 2397  3.72 (7.08) 396 4.27 (7.51) 1.07 0.94–1.23 .31 1.04 0.91–1.17 .58
Abbreviations: ART, antiretroviral therapy; CI, confidence interval; hsCRP, high-sensitivity C-reactive protein; IL-6, interleukin 6; PLWH, people living with HIV.
aModels were adjusted for covariates including age, race, gender, body mass index, time on ART, HIV exposure group, baseline viral load, baseline and nadir CD4+ T-cells, hepatitis B or C 
co-infection, smoking, and regimen type. 
b100% adherence defined as no report of any missed doses for any drug in the preceding 7-day period. 
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most interventions to date have had in reducing chronic resid-
ual inflammation in treated HIV infection, further research to 
understand the pathogenesis of residual inflammation that can 
lead to new approaches aimed at achieving this goal is needed. 
In this context, whether ART adherence optimization could 
reduce residual chronic inflammation in individuals who have 
achieved virologic suppression, or whether it could have a syn-
ergistic effect in conjunction with current and future ART strat-
egies, remains unknown and should be evaluated in prospective 
studies.
While the association between suboptimal adherence and 
enhanced residual inflammation is novel and provocative, its 
clinical translation remains unclear, in particular as it relates 
to the development of SNAEs in the virologically suppressed 
population. As chronic residual inflammation has been asso-
ciated with the development of SNAEs [2, 3], it is plausible 
that suboptimal adherence could also be responsible, at least 
in part, for the increased morbidity and mortality observed 
in treated PLWH who remain virally suppressed. To answer 
this question, future analyses evaluating the association of 
SNAEs with ART adherence in the virally suppressed popula-
tion should be performed in large clinical cohorts. This could 
be coupled with a systematic evaluation of ART adherence in 
current and future studies aimed at reducing chronic resid-
ual inflammation in HIV, and with studies in which persistent 
inflammation could lead to further evaluation of adherence 
practices.
The main strengths of our study include a large and diverse 
population of PLWH obtained within the context of a multina-
tional clinical trial and the persistently significant associations 
that were identified at lower viral suppression thresholds and 
after adjusting for multiple confounders that could contribute to 
residual inflammation, such as smoking, body mass index, nadir 
CD4+ T-cells, and others. Among its limitations are the cross-
sectional nature of the analysis and the potential for self-report 
to overestimate adherence [19], although a more objective 
adherence measure could have resulted in an even more sig-
nificant association than the one we observed with self-report. 
In addition, the thresholds for viral suppression in this study 
(<200 and <50 copies/mL) may not reflect what is currently 
used in all clinical settings, and further research to evaluate this 
association using lower viral load cutoffs (ie, <20 copies/mL) 
is required. Lastly, although this study included a wide variety 
of ART regimens, it did not include integrase strand-transfer 
inhibitors (INSTIs), which may have a more pronounced effect 
in reducing residual inflammation when compared with other 
regimens [20]. Whether the differential effect of INSTIs on 
chronic inflammation extends to individuals who are subopti-
mally adherent to ART should also be evaluated.
In conclusion, we demonstrated that suboptimal ART 
adherence, even if it results in virologic suppression by con-
ventional clinical assays, is associated with enhanced residual 
inflammation and activation of coagulation in PLWH on chronic 
ART. These findings replicate previous cohort observations and 
highlight the importance of optimal and durable ART adher-
ence as a potential factor to improve morbidity and mortality 
in HIV disease.
Supplementary Data
Supplementary materials are available at Open Forum Infectious Diseases 
online. Consisting of data provided by the authors to benefit the reader, 
the posted materials are not copyedited and are the sole responsibility of 
the authors, so questions or comments should be addressed to the corre-
sponding author.
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